

# Partow Kebriaei

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6514777/publications.pdf>

Version: 2024-02-01

307  
papers

11,264  
citations

44069

48  
h-index

34986

98  
g-index

313  
all docs

313  
docs citations

313  
times ranked

11193  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chimeric antigen receptor T-cell therapy "assessment and management of toxicities. Nature Reviews Clinical Oncology, 2018, 15, 47-62.	27.6	1,659
2	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. New England Journal of Medicine, 2020, 382, 545-553.	27.0	1,252
3	Inotuzumab ozogamicin, an anti-CD22 "calcicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncology, The, 2012, 13, 403-411.	10.7	401
4	Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. Journal of Clinical Investigation, 2016, 126, 3363-3376.	8.2	399
5	Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2009, 15, 804-811.	2.0	389
6	Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7788-E7797.	7.1	320
7	First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome "positive (Ph+) acute lymphoblastic leukemia. Blood, 2010, 116, 2070-2077.	1.4	319
8	Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen "Matched Unrelated and Related Donors. Biology of Blood and Marrow Transplantation, 2014, 20, 1975-1981.	2.0	207
9	Detection of MRD may predict the outcome of patients with Philadelphia chromosome "positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood, 2013, 122, 1214-1221.	1.4	190
10	Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome "positive acute lymphoblastic leukemia. Cancer, 2015, 121, 4158-4164.	4.1	181
11	Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nature Reviews Clinical Oncology, 2019, 16, 45-63.	27.6	178
12	Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematology, the, 2016, 3, e45-e52.	4.6	158
13	Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematology, the, 2017, 4, e387-e398.	4.6	158
14	US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Advances, 2016, 1, 250-259.	5.2	142
15	Transposon/Transposase System to Generate CD19-Specific T Cells for the Treatment of B-Lineage Malignancies. Human Gene Therapy, 2010, 21, 427-437.	2.7	124
16	Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini "Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome "Negative Acute Lymphoblastic Leukemia. JAMA Oncology, 2018, 4, 230.	7.1	124
17	Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nature Reviews Clinical Oncology, 2018, 15, 218-218.	27.6	114
18	Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 172, 392-400.	2.5	102

#	ARTICLE	IF	CITATIONS
19	Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies. <i>Human Gene Therapy</i> , 2012, 23, 444-450.	2.7	99
20	A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 835-844.	2.0	95
21	Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. <i>Bone Marrow Transplantation</i> , 2018, 53, 449-456.	2.4	92
22	Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. <i>Haematologica</i> , 2021, 106, 2667-2672.	3.5	92
23	New and emerging therapies for acute and chronic graft-versus-host disease. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 21-46.	2.5	90
24	Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. <i>Cancer</i> , 2018, 124, 4044-4055.	4.1	88
25	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) – an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 1868-1880.	2.4	86
26	Individual Motile CD4+ T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 473-482.	3.4	85
27	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e76-e85.	2.0	85
28	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2113-2123.	2.0	77
29	Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 584-592.	2.0	76
30	Results of a phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. <i>Cancer</i> , 2016, 122, 3316-3326.	4.1	75
31	Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 91-99.	4.1	74
32	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
33	Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 212-218.	0.4	71
34	Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory T-cell acute lymphoblastic leukemia. <i>Cancer</i> , 2017, 123, 294-302.	4.1	70
35	Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019, 6, e266-e275.	4.6	68
36	Treatment of graft-versus-host-disease with mesenchymal stromal cells. <i>Cytotherapy</i> , 2011, 13, 262-268.	0.7	67

#	ARTICLE	IF	CITATIONS
37	Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1059-1064.	2.0	65
38	Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. <i>Journal of Geriatric Oncology</i> , 2014, 5, 422-430.	1.0	65
39	Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1232-1236.	2.0	64
40	Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1948-1954.	2.0	63
41	Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 410-417.	2.0	61
42	Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1514-1520.	2.0	61
43	Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 47-53.	2.0	58
44	Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. <i>Lancet Haematology</i> , 2020, 7, e61-e72.	4.6	56
45	The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 319-326.	0.4	55
46	Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. <i>Blood</i> , 2016, 128, 297-312.	1.4	54
47	Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 110-117.	3.5	54
48	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 318-324.	2.0	54
49	Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. <i>Blood</i> , 2007, 110, 3456-3462.	1.4	53
50	Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1720-1729.	2.0	53
51	Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 296-301.	0.4	50
52	Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. <i>Cancer</i> , 2017, 123, 459-467.	4.1	49
53	Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 27-31.	2.0	49
54	Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1767-1771.	2.0	46

#	ARTICLE	IF	CITATIONS
55	Cytogenetics, Donor Type, and Use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1618-1625.	2.0	46
56	Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions. <i>Frontiers in Oncology</i> , 2020, 10, 1594.	2.8	46
57	Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1819-1826.	2.0	43
58	High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1677-1686.	2.0	43
59	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e523-e533.	4.6	43
60	Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood. <i>Journal of Visualized Experiments</i> , 2013, , e50070.	0.3	42
61	Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 412-420.	2.0	40
62	Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1418-1425.	2.0	40
63	Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. <i>American Journal of Hematology</i> , 2017, 92, 331-337.	4.1	39
64	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 2073-2083.	5.2	39
65	Can a Female Donor for a Male Recipient Decrease the Relapse Rate for Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation?. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 713-719.	2.0	36
66	MSCs in Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, S21-S29.	2.0	35
67	Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 906-912.	2.0	35
68	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
69	Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2166-2171.	2.0	34
70	Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. <i>Blood</i> , 2022, 139, 1908-1919.	1.4	34
71	Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. <i>Cancer</i> , 2021, 127, 2648-2656.	4.1	33
72	Better allele-level matching improves transplant-related mortality after double cord blood transplantation. <i>Haematologica</i> , 2015, 100, 1361-1370.	3.5	32

#	ARTICLE	IF	CITATIONS
73	Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2015, 50, 939-946.	2.4	32
74	Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allogeneic Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2710-2719.	1.6	32
75	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 435-453.	27.6	31
76	A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. <i>Biomedical Microdevices</i> , 2010, 12, 855-863.	2.8	30
77	Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1714-1720.	2.0	30
78	Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 687-693.	0.4	29
79	Maintenance with 5-Azacytidine for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. <i>Blood</i> , 2018, 132, 971-971.	1.4	29
80	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021, 35, 2076-2085.	7.2	28
81	Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. <i>Cancer</i> , 2016, 122, 3831-3837.	4.1	27
82	Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 1388-1395.	4.1	26
83	Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 285-292.	2.0	24
84	Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 601-606.	2.4	24
85	Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2019, 54, 839-848.	2.4	24
86	Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 2025-2038.	4.1	24
87	Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 930.e1-930.e10.	1.2	24
88	The Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Therapy of Patients with Acute Lymphoblastic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 144-152.	2.3	23
89	Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e532-e542.	4.6	23
90	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23

#	ARTICLE	IF	CITATIONS
91	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, 1000-1007.	4.1	23
92	Mesenchymal Stem Cell Therapy in the Treatment of Acute and Chronic Graft Versus Host Disease. <i>Frontiers in Oncology</i> , 2011, 1, 16.	2.8	22
93	Comprehensive Craniospinal Radiation for Controlling Central Nervous System Leukemia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1119-1125.	0.8	22
94	Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1405-1412.	2.0	22
95	Ex Vivo Mesenchymal Precursor Cellâ€“Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1359-1366.	2.0	22
96	The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e1-e5.	0.4	21
97	Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment. <i>Practical Radiation Oncology</i> , 2017, 7, e401-e408.	2.1	21
98	Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 665-671.	2.0	21
99	Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. <i>American Journal of Hematology</i> , 2019, 94, 1382-1387.	4.1	20
100	Chimeric antigen receptor Tâ€“cell therapy toxicities. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2414-2424.	2.4	19
101	Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). <i>Bone Marrow Transplantation</i> , 2022, 57, 51-56.	2.4	19
102	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
103	Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 430.e1-430.e7.	1.2	18
104	Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. <i>Bone Marrow Transplantation</i> , 2021, 56, 1316-1324.	2.4	18
105	Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 911-917.	2.4	18
106	CARs in Chronic Lymphocytic Leukemia â€“ Ready to Drive. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 60-70.	2.3	17
107	Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia. <i>Cancer</i> , 2016, 122, 3812-3820.	4.1	17
108	Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1607-1615.	1.3	17

#	ARTICLE	IF	CITATIONS
109	Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1439-1445.	2.0	17
110	An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E229-E232.	4.1	17
111	Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial. <i>Blood</i> , 2018, 132, 553-553.	1.4	17
112	Long-Term Outcomes after Treatment with Clofarabine±Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1792-1800.	2.0	16
113	Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 197-203.	2.0	16
114	Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 961-965.	2.0	15
115	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1602-1609.	2.0	15
116	Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 505-514.	2.0	15
117	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	1.2	15
118	Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 390.e1-390.e7.	1.2	15
119	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.	1.2	15
120	Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults. <i>Acta Haematologica</i> , 2014, 132, 313-325.	1.4	14
121	Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. <i>Cancer</i> , 2017, 123, 2035-2042.	4.1	14
122	Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. <i>Cancer</i> , 2017, 123, 2661-2670.	4.1	14
123	Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 689-695.	1.2	14
124	Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin's Lymphoma (NHL).. <i>Blood</i> , 2006, 108, 315-315.	1.4	14
125	Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. <i>Haematologica</i> , 2017, 102, e514-e517.	3.5	13
126	HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. <i>Current Research in Translational Medicine</i> , 2019, 67, 51-55.	1.8	13



#	ARTICLE	IF	CITATIONS
127	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	2.4	13
128	The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. <i>Seminars in Oncology Nursing</i> , 2021, 37, 151216.	1.5	13
129	A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-Hodgkin lymphomas: long term results. <i>British Journal of Haematology</i> , 2017, 178, 561-570.	2.5	12
130	Reprint of: Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S15-S19.	2.0	12
131	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 272.e1-272.e5.	1.2	12
132	Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60. <i>Blood</i> , 2015, 126, 796-796.	1.4	12
133	Stem cell transplantation outcomes in lymphoblastic lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 366-371.	1.3	11
134	Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. <i>Cancer</i> , 2017, 123, 3568-3575.	4.1	11
135	A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2018, 182, 442-444.	2.5	11
136	Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged $\geq 75$ years. <i>Leukemia and Lymphoma</i> , 2019, 60, 3536-3543.	1.3	11
137	Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1039-1044.	2.0	11
138	Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. <i>Blood Advances</i> , 2020, 4, 4834-4837.	5.2	11
139	Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. <i>Bone Marrow Transplantation</i> , 2021, 56, 2005-2012.	2.4	11
140	Low rate of infusional toxicity after expanded cord blood transplantation. <i>Cytotherapy</i> , 2014, 16, 1153-1157.	0.7	10
141	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 6781-6787.	7.0	10
142	HyperCVAD plus ofatumumab versus hyperCVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. <i>Cancer</i> , 2021, 127, 3381-3389.	4.1	10
143	Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1003.e1-1003.e13.	1.2	10
144	Experience with 2 Dose Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in Refractory-Relapsed Acute Lymphocytic Leukemia (ALL). <i>Blood</i> , 2012, 120, 671-671.	1.4	10

#	ARTICLE	IF	CITATIONS
145	First Clinical Trials Employing Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells To Generate and Infuse T Cells Expressing CD19-Specific Chimeric Antigen Receptor. <i>Blood</i> , 2013, 122, 166-166.	1.4	10
146	Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 713-719.	0.4	9
147	Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1759-1769.	2.0	9
148	Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. <i>Cancer</i> , 2021, 127, 1598-1605.	4.1	9
149	Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. <i>Haematologica</i> , 2022, 107, 899-908.	3.5	9
150	Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2021, 96, 1137-1146.	4.1	8
151	Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. <i>Leukemia and Lymphoma</i> , 2022, 63, 710-721.	1.3	8
152	Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. <i>Frontiers in Oncology</i> , 2022, 12, 818679.	2.8	8
153	Future of Therapy in Acute Lymphoblastic Leukemia (ALL)â€”Potential Role of Immune-Based Therapies. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 76-85.	2.3	7
154	Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. <i>British Journal of Haematology</i> , 2017, 177, 567-577.	2.5	7
155	Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 945-955.	2.0	7
156	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1340-1346.	2.0	7
157	Philadelphia chromosome positive acute lymphoblastic leukemia in adults: Therapeutic options and dilemmas in 2020. <i>Seminars in Hematology</i> , 2020, 57, 137-141.	3.4	7
158	Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. <i>Blood Advances</i> , 2020, 4, 1296-1306.	5.2	7
159	Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. <i>Frontiers in Oncology</i> , 2021, 11, 625707.	2.8	7
160	T Cells Demonstrate Enhanced Specificity for CD19+ Malignancies When Stimulated with IL-21. <i>Blood</i> , 2008, 112, 1539-1539.	1.4	7
161	CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 800110.	2.8	7
162	Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	7

#	ARTICLE	IF	CITATIONS
163	KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. <i>Bone Marrow Transplantation</i> , 2022, 57, 1142-1149.	2.4	7
164	Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. <i>Annals of Hematology</i> , 2019, 98, 2233-2235.	1.8	6
165	Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. <i>Haematologica</i> , 2019, 104, e555-e557.	3.5	6
166	Haploidentical transplants for patients with relapse after the first allograft. <i>American Journal of Hematology</i> , 2020, 95, 1187.	4.1	6
167	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
168	Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 913.e1-913.e12.	1.2	6
169	Outcome after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen for Adults with De Novo or Minimally Treated Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2008, 112, 2931-2931.	1.4	6
170	Allogeneic Transplantation after an Alemtuzumab-Containing Myeloablative Conditioning Regimen for CD52 Positive Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2005, 106, 1135-1135.	1.4	6
171	Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2270-2270.	1.4	6
172	Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 395.e1-395.e11.	1.2	6
173	Pre-MEASURE: Multicenter evaluation of the prognostic significance of measurable residual disease testing prior to allogeneic transplantation for adult patients with AML in first remission.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7006-7006.	1.6	6
174	Melphalan-based autologous transplant in octogenarian multiple myeloma patients. <i>American Journal of Hematology</i> , 2019, 94, E2-E5.	4.1	5
175	Haploidentical transplants for patients with graft failure after the first allograft. <i>American Journal of Hematology</i> , 2020, 95, E267.	4.1	5
176	Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1746-1749.	2.4	5
177	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>t(8;21) KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847.	5.2	5
178	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. <i>Blood</i> , 2019, 134, 261-261.	1.4	5
179	Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes. <i>Blood</i> , 2020, 136, 26-28.	1.4	5
180	Phase II Study of Combination of the HyperCVAD Regimen with Dasatinib in Patients with Philadelphia Chromosome (Ph) or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).. <i>Blood</i> , 2007, 110, 2814-2814.	1.4	5

#	ARTICLE	IF	CITATIONS
181	Zevalin®/BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.. Blood, 2007, 110, 620-620.	1.4	5
182	Phase II Study of Combination of hyperCVAD with Dasatinib in Frontline Therapy of Patients with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2008, 112, 2921-2921.	1.4	5
183	A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. Blood, 2012, 120, 4200-4200.	1.4	5
184	A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. Blood, 2015, 126, 854-854.	1.4	5
185	Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood, 2017, 130, 886-886.	1.4	5
186	Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. American Journal of Hematology, 2018, 94, E72-E74.	4.1	4
187	Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1077-1083.	2.0	4
188	Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant. Current Oncology Reports, 2021, 23, 95.	4.0	4
189	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS.. Blood, 2004, 104, 2301-2301.	1.4	4
190	Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience,. Blood, 2011, 118, 4118-4118.	1.4	4
191	Chimeric antibody receptors (CARs): Driving T-cell specificity to enhance anti-tumor immunity. Frontiers in Bioscience - Scholar, 2012, S4, 520.	2.1	3
192	Graft loss attributed to possible transfusion-transmitted ehrlichiosis following cord blood stem cell transplant. Transplant Infectious Disease, 2018, 20, e12899.	1.7	3
193	Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 404.e1-404.e5.	1.2	3
194	Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes. Leukemia and Lymphoma, 2021, 62, 2831-2844.	1.3	3
195	Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. American Journal of Hematology, 2021, 96, E455-E457.	4.1	3
196	Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission. Blood, 2020, 136, 46-48.	1.4	3
197	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan: A New Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. Blood, 2005, 106, 1159-1159.	1.4	3
198	Impact of Age on the Outcomes of HCT for AML in CR1: Promising Therapy for Older Adults. Blood, 2020, 136, 41-42.	1.4	3

#	ARTICLE	IF	CITATIONS
199	A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan±clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplantation, 0, , .	2.4	3
200	Progress in Novel Cellular Therapy Options for Chronic Lymphocytic Leukemia: The MD Anderson Perspective. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S18-S22.	0.4	2
201	Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. Journal of Medical Case Reports, 2016, 10, 209.	0.8	2
202	Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematologica, 2021, 144, 74-81.	1.4	2
203	Outcomes of Older Patients with Myeloid Leukemias Treated with Myeloablative Intravenous Busulfan-Based Conditioning Regimens and Allogeneic Blood or Marrow Transplantation.. Blood, 2005, 106, 660-660.	1.4	2
204	A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. Blood, 2008, 112, 3320-3320.	1.4	2
205	IL-7 as a Membrane-Bound Molecule for the Costimulation of Tumor-Specific T Cells.. Blood, 2009, 114, 3035-3035.	1.4	2
206	Stem Cell Transplantation with 90Yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.. Blood, 2009, 114, 868-868.	1.4	2
207	Fluid Overload As New Toxicity Category Has a Strong Impact on Non Relapse Mortality and Survival in Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 4321-4321.	1.4	2
208	Outcome of Autologous Stem Cell Transplantation in Myeloma Patients Aged ≥ 75 Years. Blood, 2016, 128, 3453-3453.	1.4	2
209	High-Dose Topotecan, Melphalan and Cyclophosphamide (TMC) with Autologous Stem Cell Support for Multiple Myeloma. Blood, 2008, 112, 4452-4452.	1.4	2
210	Nonmyeloablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd. Blood, 2011, 118, 894-894.	1.4	2
211	Phase II study of umbilical cord blood-derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM).. Journal of Clinical Oncology, 2022, 40, 8009-8009.	1.6	2
212	Prolonged neurotoxicity in a lymphoma patient after CD19-directed CAR T cell therapy: A case report and brief review of the literature. Advances in Cell and Gene Therapy, 2021, 4, e104.	0.9	1
213	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 243.e1-243.e6.	1.2	1
214	Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study. Blood, 2018, 132, 4031-4031.	1.4	1
215	Arsenic Trioxide with Ascorbic Acid and High-Dose Melphalan for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma.. Blood, 2006, 108, 3090-3090.	1.4	1
216	HLA-DP Mismatches Increase the Risk of Acute GVHD after Unrelated Donor Hematopoietic Transplantation (UDT).. Blood, 2006, 108, 3125-3125.	1.4	1

#	ARTICLE	IF	CITATIONS
217	Myeloablative Chemotherapy for T-Cell Lymphoma: a Case for Autologous Stem Cell Transplantatin (Auto) in First Remission.. Blood, 2008, 112, 1141-1141.	1.4	1
218	Impact of Pretransplant Cytogenetics and Marrow Remission Status on Outcome of Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation Conditioned with Busulfan and Fludarabine. Blood, 2008, 112, 341-341.	1.4	1
219	Third Generation Chimeric Antigen Receptors Containing CD137 or CD134 Signaling Endodomains Augment CD19-Specific T-Cell Effector Function.. Blood, 2009, 114, 4097-4097.	1.4	1
220	Prognostic Impact of CD20 and CD25 Expression in Patients with Philadelphia-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL).. Blood, 2009, 114, 984-984.	1.4	1
221	EBMT Risk Score for Pre Transplant Risk Assessment in Patients with Multiple Myeloma.. Blood, 2012, 120, 3094-3094.	1.4	1
222	Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment. Blood, 2016, 128, 2916-2916.	1.4	1
223	Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy.. Journal of Clinical Oncology, 2019, 37, 7047-7047.	1.6	1
224	Fixed-Dose Single Agent Pegfilgrastim for Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma (MM).. Blood, 2005, 106, 2923-2923.	1.4	1
225	A Non-Myeloablative Regimen of Fludarabine and Melphalan Is Safe and Well Tolerated for Allogeneic Transplantation in Multiple Myeloma.. Blood, 2007, 110, 3032-3032.	1.4	1
226	Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) and Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS. Blood, 2008, 112, 2999-2999.	1.4	1
227	Autologous Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL).. Blood, 2009, 114, 2310-2310.	1.4	1
228	Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 4354-4354.	1.4	1
229	Sequential Treatment After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia.. Blood, 2012, 120, 3129-3129.	1.4	1
230	A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS. Blood, 2019, 134, 257-257.	1.4	1
231	The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleuce (axi-cel) for Non-Hodgkin Lymphoma (NHL). Blood, 2020, 136, 17-18.	1.4	1
232	Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. Blood, 2020, 136, 34-35.	1.4	1
233	Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy. Blood, 2020, 136, 13-14.	1.4	1
234	African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. Blood, 2020, 136, 9-10.	1.4	1

#	ARTICLE	IF	CITATIONS
235	Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 24-25.	1.4	1
236	CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 23-25.	1.4	1
237	Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 307.e1-307.e8.	1.2	1
238	External validation of the <sc>HIGH&#x2013;LOW</sc> model: A predictive score for venous thromboembolism after allogeneic transplant. <i>American Journal of Hematology</i> , 2022, 97, 740-748.	4.1	1
239	Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7536-7536.	1.6	1
240	First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2679-TPS2679.	1.6	1
241	Large scale generation of genetically modified T-cells using micro-electroporators for cancer treatments. , 2009, , .		0
242	Allo-transplant for older patients with acute lymphoblastic leukemia: does it work?. <i>Leukemia and Lymphoma</i> , 2015, 56, 2753-2754.	1.3	0
243	Toward a cure in relapsed ALL: we must do better. <i>Leukemia and Lymphoma</i> , 2020, 61, 2544-2545.	1.3	0
244	Advances in Cellular Immunotherapy in Hematologic Malignancies. <i>Advances in Oncology</i> , 2021, 1, 223-236.	0.2	0
245	Allogeneic Transplantation for Adult Acute Lymphoblastic Leukemia (ALL) with Rituximab or Campath I-H.. <i>Blood</i> , 2004, 104, 5132-5132.	1.4	0
246	The Impact of Rituximab in the Development of Acute Graft Versus Host Disease (GVHD) Following Allogeneic Stem Cell Transplantation (SCT) for Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2005, 106, 1803-1803.	1.4	0
247	Campath-IH Combined with Fludarabine/Cyclophosphamide/Rituximab (FCR) as Conditioning for Unrelated Non-Myeloablative Hematopoietic Transplantation (NMT) for Non-Hodgkin&#x2019;s Lymphoma (NHL): Low Mortality Rate and Lower Than Expected Incidence of Cytomegalovirus (CMV) Reactivation.. <i>Blood</i> , 2005, 106, 2902-2902.	1.4	0
248	Natural History of AML / MDS Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Using Reduced Intensity (RIC) Preparative Regimens.. <i>Blood</i> , 2005, 106, 2019-2019.	1.4	0
249	High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkin&#x2019;s Lymphoma (NHL) in Patients over 65 Years of Age.. <i>Blood</i> , 2006, 108, 3059-3059.	1.4	0
250	Autologous Stem Cell Transplantation for Elderly Patients with Multiple Myeloma.. <i>Blood</i> , 2006, 108, 5422-5422.	1.4	0
251	Deletion of the Short Arm of Chromosome 1 (del 1p) Is the Strongest Predictor of Poor Outcome in Myeloma Patients Undergoing an Autotransplant.. <i>Blood</i> , 2006, 108, 3101-3101.	1.4	0
252	Chemotherapy with Granulocyte Colony Stimulating Factor (G-CSF) Alone Versus Granulocyte Colony Stimulating Factor (G-CSF) Plus Granulocyte-Macrophage Stimulating Factor (GM-CSF) for Hematopoietic Progenitor Cell Mobilization in Patients with Relapsed Non-Hodgkin&#x2019;s Lymphomas (NHLs).. <i>Blood</i> , 2007, 110, 1900-1900.	1.4	0

#	ARTICLE	IF	CITATIONS
253	A Comparison of 1 Antigen-Mismatched Related and Matched Unrelated Transplants.. Blood, 2007, 110, 3051-3051.	1.4	0
254	Cardiac Toxicity and Non-Relapse Mortality in Patients with Low Left Ventricular Ejection Fraction Undergoing Stem Cell Transplantation.. Blood, 2007, 110, 3002-3002.	1.4	0
255	CD19-Specific T Cells for Treatment of Pediatric Acute Lymphocytic Leukemia Using Sleeping Beauty Transposition.. Blood, 2007, 110, 2820-2820.	1.4	0
256	Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.. Blood, 2008, 112, 1128-1128.	1.4	0
257	Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma. Blood, 2008, 112, 3298-3298.	1.4	0
258	Platelet Recovery Prior to Stem Cell Transplantation Predicts for Post- Transplant Outcomes in Patients with AML. Blood, 2008, 112, 3000-3000.	1.4	0
259	An Analysis of the Costs Associated with Peripheral Blood Hematopoietic Progenitor Cell Mobilization, Collection and Cryopreservation in Patients with Lymphomas Undergoing Autologous Stem Cell Transplantation. Blood, 2008, 112, 2377-2377.	1.4	0
260	Donor Type Impacts the Incidence of Severe Acute but Not Chronic Graft- Versus-Host Disease (GVHD) after Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation (ASCT) for Treatment of AML/MDS.. Blood, 2008, 112, 2227-2227.	1.4	0
261	Reduced Intensity Conditioning (RIC) Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Adult Patients with Acute Lymphoblastic Leukemia (ALL). Blood, 2008, 112, 4326-4326.	1.4	0
262	Addition of Umbilical Cord Blood (UCB) Unit to Reduced Intensity Conditioning (RIC) Regimen to Augment Graft Versus Tumor (GVT) in Patients (pts) with Advanced Hematologic Malignancies. Blood, 2008, 112, 3297-3297.	1.4	0
263	Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS. Blood, 2008, 112, 799-799.	1.4	0
264	Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).. Blood, 2009, 114, 3213-3213.	1.4	0
265	A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma.. Blood, 2009, 114, 2309-2309.	1.4	0
266	Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem Cell Transplantation (ASCT): Allografting Vs. Conventional Therapy. Blood, 2010, 116, 3510-3510.	1.4	0
267	Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. Blood, 2010, 116, 2341-2341.	1.4	0
268	Sequential Therapy with Allogeneic Transplant Followed by Low-Dose Azacitidine for CML Patients That Failed Multiple Tyrosine Kinase Inhibitors. Blood, 2011, 118, 3106-3106.	1.4	0
269	Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. Blood, 2011, 118, 2006-2006.	1.4	0
270	Relevance and Factors Predicting for Early Lymphocyte Recovery After Allogeneic Bone Marrow Stem Cell Transplantation (BMT).. Blood, 2012, 120, 3053-3053.	1.4	0



#	ARTICLE	IF	CITATIONS
271	Mesenchymal Stem Cells as Therapy for Graft Versus Host Disease: What Have We Learned?. , 2013, , 173-190.		0
272	Impact of monosomal karyotype and FLT3 status on post-transplant relapse in acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2013, 31, 7010-7010.	1.6	0
273	Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblastic Leukemia (ALL) With First Complete Remission (CR). Blood, 2013, 122, 2142-2142.	1.4	0
274	Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 3358-3358.	1.4	0
275	Autologous stem cell transplantation in dialysis-dependent myeloma patients.. Journal of Clinical Oncology, 2014, 32, 8601-8601.	1.6	0
276	Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma.. Journal of Clinical Oncology, 2014, 32, 8538-8538.	1.6	0
277	Comparable Outcomes of Therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 2276-2276.	1.4	0
278	Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. Blood, 2018, 132, 4607-4607.	1.4	0
279	Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disease Risk Index. Blood, 2019, 134, 4603-4603.	1.4	0
280	Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allogeneic Transplantation. Blood, 2019, 134, 3596-3596.	1.4	0
281	Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression. Blood, 2019, 134, 4598-4598.	1.4	0
282	Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Blood, 2021, 138, 1802-1802.	1.4	0
283	Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2021, 138, 1779-1779.	1.4	0
284	A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. Blood, 2021, 138, 3941-3941.	1.4	0
285	Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial. Blood, 2020, 136, 40-42.	1.4	0
286	Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 18-19.	1.4	0
287	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Blood, 2020, 136, 22-22.	1.4	0
288	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. Blood, 2020, 136, 17-18.	1.4	0

#	ARTICLE	IF	CITATIONS
289	Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee. <i>Blood</i> , 2020, 136, 27-29.	1.4	0
290	A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab. <i>Blood</i> , 2020, 136, 2-4.	1.4	0
291	Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis. <i>Blood</i> , 2020, 136, 42-43.	1.4	0
292	Role of Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 39-41.	1.4	0
293	Transplant Outcomes with Fludarabine and Melphalan in High Risk AML Patients By Donor Types. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
294	Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. <i>Blood</i> , 2020, 136, 10-12.	1.4	0
295	Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 20-21.	1.4	0
296	Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Outcomes of Prospective Phase II Clinical Trial. <i>Blood</i> , 2020, 136, 10-11.	1.4	0
297	Minimal Residual Disease Eradication with Guadecitabine (SGI-110) in the Post-Transplant Setting. <i>Blood</i> , 2020, 136, 10-11.	1.4	0
298	Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 45-47.	1.4	0
299	Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse. <i>Blood</i> , 2020, 136, 36-38.	1.4	0
300	Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. <i>Blood</i> , 2020, 136, 14-15.	1.4	0
301	Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 23-24.	1.4	0
302	Prognostic Value of Delta Lymphocyte Index (DLI <sub>x</sub> ) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>Blood</i> , 2020, 136, 23-24.	1.4	0
303	Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
304	A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. <i>Blood</i> , 2020, 136, 37-38.	1.4	0
305	TIP: A phase I/II study of MGTA-117, an anti-CD117 antibody-drug conjugate, in patients with adult acute myeloid leukemia (AML) and myelodysplasia with excess blasts (MDS-EB).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3156-TPS3156.	1.6	0
306	Lenalidomide: Based maintenance after autologous hematopoietic stem cell transplant for patients with high-risk multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20024-e20024.	1.6	0

#	ARTICLE	IF	CITATIONS
307	Long-term outcomes of newly diagnosed CRLF2 rearranged B-cell ALL.. Journal of Clinical Oncology, 2022, 40, 7040-7040.	1.6	0